| Autor: |
Ilaria Trave, Claudia Micalizzi, Emanuele Cozzani, Giulia Gasparini, Aurora Parodi |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Dermatology Practical & Conceptual, Vol 12, Iss 4 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2160-9381 |
| DOI: |
10.5826/dpc.1204a201 |
| Popis: |
Background: Topical ivermectin is an anti-inflammatory and anti-Demodex drug for papulopustular rosacea. Rosacea is a relapsing disease and the time between recurrences should be considered alongside efficacy Objectives: The aims of this study were to assess the time of first relapse and relapse rates of Demodex mite infestation and papulopustular rosacea Methods: We conducted a prospective study of subjects affected by different degrees of papulopustular rosacea. Patients that achieved a complete response after treatment were monitored every 4 weeks and up to 32 additional weeks. For each patient, we evaluated recording the time to first relapse and relapse rate of Demodex mite infestation and rosacea. Results: The overall success rate on Demodex infestation was 87.5%. only 12.5% relapse. Ivermectin leads to complete response in 70% of patients. Median time to relapse was 140 days, the mean time was 152 days. The global success rate was 54.76%. Conclusions: Topical ivermectin keeps a remission of Demodex infestation and clinical remission for long time. We proposed a twice-weekly ivermectin maintenance therapy to reduce recurrences. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
